News from compugen ltd. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 27, 2023, 09:00 ET Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Aug 31, 2023, 07:00 ET Compugen to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Aug 07, 2023, 07:00 ET Compugen Reports Second Quarter 2023 Results

Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal...

Jul 24, 2023, 07:00 ET Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Jul 17, 2023, 07:00 ET Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Jun 22, 2023, 07:00 ET Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Jun 13, 2023, 07:00 ET Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced...

Jun 05, 2023, 07:00 ET Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer

COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encouraging confirmed durable partial responses (overall response rate...

May 15, 2023, 07:00 ET Compugen Reports First Quarter 2023 Results

On track to deliver initial findings from studies with the triple blockade of PVRIG, TIGIT and PD-1 in patients with MSS CRC and platinum resistant...

May 11, 2023, 07:00 ET Compugen to Host DNAM-1 Axis Virtual Investor Event with KOL Drew Pardoll on Tuesday, May 23, 2023

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

May 09, 2023, 07:00 ET Compugen to Present at the JMP Securities Life Sciences Conference

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

May 01, 2023, 07:00 ET Compugen to Release First Quarter 2023 Results on Monday, May 15, 2023

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Apr 27, 2023, 07:00 ET Compugen to Present New Clinical Data Showing Preliminary Anti-Tumor Activity of COM701 Triple Combination in Recurrent MSS-Metastatic Endometrial Cancer at ASCO 2023

Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Apr 26, 2023, 07:00 ET Compugen to Present Data on its Lead Pre-Clinical Asset COM503 in an Oral Presentation at the 20th CIMT Annual Meeting

Compugen Ltd. (Nasdaq: CGEN) (TASE:CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Mar 15, 2023, 07:00 ET Compugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Mar 08, 2023, 07:00 ET Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Mar 06, 2023, 07:00 ET Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the ...

Feb 27, 2023, 07:00 ET Compugen Reports Fourth Quarter and Full Year 2022 Results

Compugen Ltd. (Nasdaq: CGEN), ("Compugen", the "Company"), a clinical-stage cancer immunotherapy company and pioneer in computational target...

Feb 14, 2023, 07:00 ET Rilvegostomig, AstraZeneca's Bi-specific Antibody Derived from Compugen's COM902, Expected to Progress into Phase 3

Phase 3 study with rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq:AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in...

Feb 13, 2023, 07:00 ET Compugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023

Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the ...

Feb 09, 2023, 07:00 ET Compugen to Present at the SVB Securities Global Biopharma Conference

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that...

Jan 23, 2023, 07:00 ET Compugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape Overview

Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat ...

Dec 06, 2022, 07:00 ET Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed...

Dec 01, 2022, 07:00 ET Compugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer Patients

At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease...

Nov 29, 2022, 07:00 ET Compugen to Participate in the JMP Securities Hematology and Oncology Summit

Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today that Anat ...